Advances in Mesenchymal Stem Cell Research Applications for Female Infertility-Mechanisms, Efficacy Parameters, Challenges and Future Roadmap.

IF 0.5 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Galen Medical Journal Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI:10.31661/gmj.v13i.3632
Sina Vakili, Morteza Jafarinia
{"title":"Advances in Mesenchymal Stem Cell Research Applications for Female Infertility-Mechanisms, Efficacy Parameters, Challenges and Future Roadmap.","authors":"Sina Vakili, Morteza Jafarinia","doi":"10.31661/gmj.v13i.3632","DOIUrl":null,"url":null,"abstract":"<p><p>Infertility affects approximately 15-20% of couples globally, with female factors contributing to nearly half of cases. Conditions such as polycystic ovary syndrome, endometriosis, tubal damage and premature ovarian failure are leading causes of female infertility. Current treatments like in vitro fertilization (IVF) have limitations and risks. Mesenchymal stem cells (MSCs) have shown therapeutic potential due to their ability to differentiate, secrete trophic factors, and exhibit immunomodulatory and anti-inflammatory properties. They have been demonstrated to repair and regenerate reproductive organs in various preclinical models of infertility related conditions. MSCs have reduced endometriotic lesions, regenerated lost follicles in premature ovarian failure (POF) models, and promoted tubal repair in damage models. Some clinical and preclinical studies have reported improved outcomes with MSC therapy in endometriosis and premature ovarian failure patients. This review discusses the properties and sources of MSCs, their mechanisms of action, preclinical evidence for applications in conditions like POF, polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia, and preliminary clinical data on MSC therapy for female infertility management.</p>","PeriodicalId":44017,"journal":{"name":"Galen Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525105/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Galen Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31661/gmj.v13i.3632","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Infertility affects approximately 15-20% of couples globally, with female factors contributing to nearly half of cases. Conditions such as polycystic ovary syndrome, endometriosis, tubal damage and premature ovarian failure are leading causes of female infertility. Current treatments like in vitro fertilization (IVF) have limitations and risks. Mesenchymal stem cells (MSCs) have shown therapeutic potential due to their ability to differentiate, secrete trophic factors, and exhibit immunomodulatory and anti-inflammatory properties. They have been demonstrated to repair and regenerate reproductive organs in various preclinical models of infertility related conditions. MSCs have reduced endometriotic lesions, regenerated lost follicles in premature ovarian failure (POF) models, and promoted tubal repair in damage models. Some clinical and preclinical studies have reported improved outcomes with MSC therapy in endometriosis and premature ovarian failure patients. This review discusses the properties and sources of MSCs, their mechanisms of action, preclinical evidence for applications in conditions like POF, polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia, and preliminary clinical data on MSC therapy for female infertility management.

间充质干细胞应用于女性不孕症研究的进展--机理、疗效参数、挑战和未来路线图。
全球约有 15-20% 的夫妇患有不孕症,其中近一半是女性因素造成的。多囊卵巢综合症、子宫内膜异位症、输卵管损伤和卵巢早衰等疾病是导致女性不孕的主要原因。体外受精(IVF)等现有治疗方法存在局限性和风险。间充质干细胞(MSCs)具有分化、分泌营养因子、免疫调节和抗炎的能力,因此具有治疗潜力。在各种与不孕症相关的临床前模型中,它们已被证明可以修复和再生生殖器官。间充质干细胞可减少子宫内膜异位症病变,在卵巢早衰(POF)模型中使失去的卵泡再生,并在损伤模型中促进输卵管修复。一些临床和临床前研究报告称,间充质干细胞治疗子宫内膜异位症和卵巢早衰患者的效果有所改善。本综述讨论了间充质干细胞的特性和来源、作用机制、应用于POF、多囊卵巢综合征(PCOS)、子宫内膜异位症、阿舍曼综合征和子痫前期等疾病的临床前证据,以及间充质干细胞治疗女性不孕症的初步临床数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Galen Medical Journal
Galen Medical Journal MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
13
期刊介绍: GMJ is open access, peer-reviewed journal in English and supported by Noncommunicable Diseases (NCD) Research Center of Fasa University of Medical Sciences that publishing by Salvia Medical Sciences Ltd. GMJ will consider all types of the following scientific papers for publication: - Editorial’s choice - Original Researches - Review articles - Case reports - Case series - Letter (to editors, to authors, etc) - Short communications - Medical Idea
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信